Theravance Biopharma, Inc.: 1 tracked 2026 layoff event(s), 0 workers counted, highest AI score 4.
AI score 4 (80% interval 3–4) · evidence grade D · US · Pharma / Chemicals
Stated reason: On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash …
Why 4: Plant, store or site closure · Drivers: contrary evidence −0.6, industry AI exposure +0.5, role AI exposure +0.1
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary 0.4 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
